Skip to content
DataLookout
Menu

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins clinical trial pipeline

Get alerts when Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

15 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 9 with minor changes only.

  1. Minor: Nivolumab With or Without Stereotactic Radiosurgery · Recurrent, Advanced, or Metastatic Chordoma Trial completed Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1 NCT02989636
  2. Notable: TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Results posted: Nov 6, 2026 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT02452008
  3. Notable: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer Results posted: Nov 4, 2026 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT04753879
  4. Minor: KIEO · Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN) Primary completion pushed from Oct 16, 2026 to Dec 2026 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT05977907
  5. Minor: Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection Enrollment increased: 150 → 200 participants Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNot specified NCT05585684
  6. Notable: Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC) Start date pushed from Oct 1, 2026 to Dec 1, 2026 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNot specified NCT07793240
  7. Notable: Nivolumab With or Without Relatlimab · Potentially Resectable Hepatocellular Carcinoma Results posted: Oct 28, 2026 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1 NCT04658147
  8. Notable: IRIS · Sarilumab With Immune Checkpoint Inhibitor Rechallenge · Clinically Significant Immune Related Adverse Events Start date pushed from Oct 2026 to Dec 2026 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT07836101
  9. Minor: Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer Enrollment closed, study ongoing Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT06617923
  10. Minor: Allogeneic HPV-specific T Cells · Recurrent or Metastatic HPV16+ Cancers Primary and study completion pushed from Oct 1, 2026 to Dec 1, 2026 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1/2 NCT04713046
  11. Minor: GLAD-KE · GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma Primary completion pushed from Oct 15, 2029 to Nov 15, 2029 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNot applicable NCT07852975
  12. Minor: DRP-104 (Glutamine Antagonist) in Combination With Durvalumab · Advanced Stage Fibrolamellar Carcinoma (FLC) Enrollment closed, study ongoing Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1/2 NCT06027086
  13. Minor: Blinatumomab · Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Primary and study completion pushed from Oct 30, 2026 to Dec 30, 2026 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1/2 NCT03114865
  14. Notable: Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme Primary completion pushed from Aug 2026 to Apr 2027 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT02177578
  15. Minor: Pertuzumab and Trastuzumab as Neoadjuvant Treatment · HER2-Positive Breast Cancer Study completion pushed from Jun 2027 to Dec 2027 Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 NCT01937117
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Active trials by phase

Early Phase 1
5
Phase 1
20
Phase 1/2
7
Phase 2
47
Not charted: 31 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 33

Get alerts when Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free